开发基于溶瘤病毒递送 CD19 和 EGFRvIII 抗原与双特异性 CAR 的胶质母细胞瘤多模式治疗
Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs.
FRONTIER PAPERS
Developing a multimodal therapy for glioblastoma using oncolytic virus delivering CD19 and EGFRvIII antigens and bi-specific CARs.
Engineered probiotics recruit CAR macrophages and establish immune memory to eradicate heterogeneous glioblastoma in mice.
Enable CAR T cell immunotherapy in glioblastoma by modifying its microenvironment via oncolytic adenovirus encoding bispecific T cell engager.
The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma.
A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma.
Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy.
Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review.
Enabling CAR-T Cell Immunotherapy in Glioblastoma by Modifying Tumor Microenvironment via Oncolytic Adenovirus Encoding Bispecific T Cell Engager.
共 8 条
MEMBER ACCOUNT
登录成功会直接打开下一页。